Ahmad Salah, DO
Rheumatology · Merrillville, INNPI 1285909481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $104,575 of the $139,215 with a category attached, or 75.1%. 35 manufacturers reported payments, led by AbbVie at 52.1% of the total. 2025 is the largest year on record at $65,279, more than ten times the $2,560 reported in 2019. Among rheumatology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 719 payments — averaging $193.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$73K
- AstraZeneca$55K
- Johnson & Johnson$3K
- Sobi, Inc$2K
- Amgen$1K
- Novartis$1K
- plus $5K from 29 others
Across 1 payment — averaging $4593.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Consulting fees$3,5933%
- Speaking & faculty fees$104,57575%
- Travel & lodging$16,05312%
- Food & beverage$14,51710%
- Education$4770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 241 | $72,588 |
| AstraZeneca(2 entities) | 100 | $54,951 |
| Johnson & Johnson | 47 | $2,552 |
| Sobi, Inc | 5 | $2,149 |
| Amgen(2 entities) | 71 | $1,335 |
| Novartis | 51 | $1,032 |
| ANI Pharmaceuticals, Inc. | 32 | $941 |
| E.r. Squibb & Sons, L.L.C. | 29 | $668 |
| Sanofi | 20 | $562 |
| GSK | 30 | $447 |
| UCB, Inc. | 16 | $357 |
| Pfizer | 19 | $251 |
| Genentech USA, Inc. | 8 | $241 |
| Lilly USA, LLC | 9 | $183 |
| Mallinckrodt Hospital Products Inc. | 5 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Radius Health, Inc. | 5 | $98 |
| Octapharma USA, Inc. | 3 | $85 |
| Abbott | 1 | $79 |
| Bristol Myers Squibb | 3 | $68 |
| Medexus Pharma, Inc. | 5 | $59 |
| Vertex | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Boehringer Ingelheim | 2 | $37 |
| Sandoz | 1 | $33 |
| Merck | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $23 |
| Organon | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$53,149
- Rinvoq$46,875
- Skyrizi$22,572
- Tremfya$1,680
- PURIFIED CORTROPHIN GEL$569
How this compares
$139,215 in reported general payments places this provider in the 95th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 193 | $1,336,033 |
| Humira(Cf) PenAdalimumab | 122 | $1,163,298 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 30 | $228,509 |
| Enbrel SureclickEtanercept | 29 | $224,717 |
| Orencia ClickjectAbatacept | 31 | $182,974 |
| KevzaraSarilumab | 35 | $182,633 |
| EnbrelEtanercept | 24 | $178,616 |
| OtezlaApremilast | 26 | $127,073 |
| Taltz AutoinjectorIxekizumab | 15 | $126,325 |
| Actemra ActpenTocilizumab | 34 | $102,868 |
| Cosentyx Sensoready PenSecukinumab | 11 | $101,958 |
| Cosentyx (2 Syringes)Secukinumab | 11 | $81,061 |
| Xeljanz XrTofacitinib Citrate | 12 | $80,790 |
| ActemraTocilizumab | 12 | $26,298 |
| Mycophenolate Mofetil | 44 | $8,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $72,588 | $1,336,033193 claims |
| AmgenEnbrel, Otezla | $1,335 | $305,68950 claims |
| SanofiKevzara | $562 | $182,63335 claims |
| NovartisCosentyx (2 Syringes) | $1,032 | $81,06111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Merrillville
- Larry BrazleyMerrillville$3K
- David BattIndianapolis$577K
- Kathleen ThomasNoblesville$511K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Nina RamessarFort Wayne$75K
- Anita ZachariahMunster$37K
- James EhlichIndianapolis$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.